Pharma

Owing to various reasons, the demand for cell therapies is anticipated to increase over the coming years. Therefore, both therapy developers and contract service providers may need to strengthen their capabilities and expand available capacity. In this context, automation is expected to be a key enabler within the cell therapy manufacturing and contract services industry […]

Roots Analysis has done a detailed study on Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030, covering various important aspects of the industry and identifying key future growth opportunities. To order this 550+ page report, which features 160+ figures and 250+ tables, please visit this link Key Market Insights More than 100 industry players

Manufacturing cell therapies is technically and financially demanding; as a result, despite therapy developers gradually strengthening their in-house expertise, they are also becoming increasingly reliant on contract service providers Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030.” The report features an

The approval of KYMIRAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessity Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 – 2030” report to its list of

To order this detailed 300+ page report, please visit this link Key Inclusions A detailed assessment of the current market landscape, including information on drug developer(s), A detailed assessment of the current market landscape of companies offering patient recruitment and retention services, including information on over 10 types of patient outreach methods employed, types of

A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers. Presently, close to 140 companies are actively offering patient recruitment and retention services. Majority of these players possess vast service portfolios and

Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Market, 2019-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 300+ page report, which features 90+ figures and 140+ tables, please visit this link Key Market Insights Presently, close to 140 companies claim to

A steadily increasing demand for participants in clinical research studies, coupled to the complexities associated with patient enrolment, have prompted drug / therapy developers to outsource this process to specialty service providers Roots Analysis  is pleased to announce the publication of its recent study, titled, “Patient Recruitment and Retention Services Marker, 2019-2030.” The report offers

To order this 750+ page report, please visit this link Key Inclusions A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial),

Owing to the ever-increasing number of start-ups that are involved in R&D of novel biologics, there is an enormous opportunity for the CMOs in this domain. It is worth emphasizing that, since 2000, more than 115 new CMOs have been established in order to serve to the growing demand for novel biologics that have specific